Retina

RG7716 molecule shows promise as DME treatmentPravin U. Dugel, MD, reports that if potential phase III studies for RG7716 replicate outcomes from its phase II study, this bi-specific molecule could be the first for the treatment of retinal disease.
Plasma-free VEGF level decreases with aflibercept, bevacizumabCompared with intravitreous ranibizumab, the decreases in the plasma-free VEGF levels were greater with intravitreous aflibercept and bevacizumab in patients with diabetic macular edema.
Failed lampalizumab studies offer numerous lessons about GAAlthough the phase III Chroma and Spectri studies for lampalizumab (Genentech), an investigational compound for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD), failed to meet their primary endpoints, numerous lessons can be learned from the study data.
Distinction between lamellar holes and macular pseudoholesLamellar holes usually don’t require treatment, but it is important to recognize the eyes that may benefit from vitrectomy.
‘Hypersonic’ vitrectomy overcomes flaws of traditional systemsUsing ultrasonic power to actuate a vitrectomy probe (hypersonic vitrectomy) allows for a “smooth steady flow of vitreous into a port that is oscillating at 1.7 million cycles per minute,” according to Carl C. Awh, MD.
Aflibercept shows macular perfusion gains in VISTA subanalysisThe use of aflibercept led to greater improvement in macular perfusion status in a phase III trial with DME patients. Those with baseline nonperfusion tended to have more advanced disease.
AMD trial data are highlights at recent conferencesClinical trial data focusing on treatment for age-related macular degeneration (AMD) have been a highlight at many recent ophthalmology meetings. Here are a few of the latest clinical trials that physicians need to be aware.
Sequenced approach offers effective retinectomy with less complicationsA retinectomy performed under air using a sequenced approach can improve outcomes.
Resolve patient confusion with AMD awareness, understandingAge-related macular degeneration (AMD) is the leading cause of significant visual acuity loss in people over the age of 50 in developed countries. Almost 80% of the people diagnosed with AMD will have the non-neovascular (dry) or atrophic subtypes. Here is the clinical information patients need to understand this disease.
Most-talked-about journal articles bring ‘awareness’ to AMDTwo of the top 10 “most-talked-about” articles in JAMA Ophthalmology are about age-related macular degeneration (AMD). One of the current top 5 “most-read” articles in the American Journal of Ophthalmology is also about AMD. Here are a brief synopsis of those three papers.